GRAPHIC APPEARS HERE] May 1, 2003 Michael Kelly, Ph.D. Re: Amendment to Renovis, Inc. Offer Letter Dear Mike:Renovis Inc • January 16th, 2004 • Pharmaceutical preparations
You and Renovis, Inc. (the “Company”) are parties to an offer letter dated November 15, 2002 (the “Offer Letter”), which sets forth, among other things, the terms of your employment with the Company. The Company would like to amend the Offer Letter as provided below to provide you with certain severance benefits in the event of a termination of your employment without Cause (as defined below) or your Constructive Termination (as defined below). This letter agreement supersedes any other agreement or policy to which the Company is a party with respect to any severance benefits payable to you and any acceleration of vesting of your stock options or restricted stock as a result of your termination of employment.
EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and RENOVIS, INC. for METHOD OF TREATING PAIN USING NALBUPHINE AND OPIOID ANTAGONISTS UC Case No. 2000-002Exclusive License Agreement • January 16th, 2004 • Renovis Inc • Pharmaceutical preparations • California
This license agreement (the “Agreement”) is made and entered into effective as of December 27, 2002 (the “Effective Date”) by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200, (“The Regents”), and acting through its Office of Technology Management, University of California San Francisco, 185 Berry Street, Suite 4603, San Francisco, CA 94107 (“UCSF”), and RENOVIS, INC., a Delaware corporation having a principal place of business at 270 Littlefield Avenue, South San Francisco, CA 94080 (the “Licensee”).
Underwriting AgreementUnderwriting Agreement • January 16th, 2004 • Renovis Inc • Pharmaceutical preparations • New York
Renovis, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of shares (the “Firm Shares”) and, at the election of the Underwriters, up to additional shares (the “Optional Shares”) of common stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being herein collectively called the “Shares”).
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Between RENOVIS, INC. and GENENTECH, INC.And License Agreement • January 16th, 2004 • Renovis Inc • Pharmaceutical preparations • California
THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), entered into as of December 31, 2003 (the “Effective Date”), by and between RENOVIS, INC., a Delaware corporation (“Renovis”), with offices at Two Corporate Drive, South San Francisco, CA 94080, and GENENTECH, INC., a Delaware corporation (“Genentech”), with offices at 1 DNA Way, South San Francisco, California 94080. Renovis and Genentech may each be referred to herein individually as a “Party” and collectively as the “Parties.”
PATENT LICENSE AND RESEARCH COLLABORATION AGREEMENT between MERCK & CO., INC. and RENOVIS, INC.Patent License and Research Collaboration Agreement • January 16th, 2004 • Renovis Inc • Pharmaceutical preparations • New York
THIS AGREEMENT (the “Agreement”), effective as of July 15, 2003 (the “Effective Date”), is entered into by and between Merck & Co., Inc., a corporation organized and existing under the laws of the state of New Jersey (“MERCK”), and Renovis, Inc., a corporation organized and existing under the laws of the state of Delaware (“RENOVIS”).
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT FOR AXON GROWTH TECHNOLOGIESThe Exclusive License Agreement • January 16th, 2004 • Renovis Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT FOR AXON GROWTH TECHNOLOGIES (the “Amendment”) is made and entered into effective as of December 23rd, 2003 (the “Amendment Effective Date”), by and between RENOVIS, INC., a Delaware corporation (“Renovis”) having its place of business at Two Corporate Drive, South San Francisco, CA 94080, and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation (“The Regents”) whose legal address is 1111 Franklin Street, 12 Floor, Oakland, California 94607-5300, acting through its Office of Technology Licensing at the University of California, Berkeley, California 94720-1620. Renovis and The Regents may be referred to herein as a “Party” or, collectively, as “Parties”.
FIRST AMENDMENT TO LICENSE AGREEMENT FOR [*]/SMALL MOLECULE, AND [*] PROTEIN TECHNOLOGIESCertain • January 16th, 2004 • Renovis Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT TO THE LICENSE AGREEMENT FOR [*]/SMALL MOLECULE, AND [*] PROTEIN TECHNOLOGIES (the “Amendment”) is made and entered into effective as of December 22nd, 2003 (the “Amendment Effective Date”), by and between RENOVIS, INC., a Delaware corporation (“Renovis”) having its place of business at Two Corporate Drive, South San Francisco, CA 94080, and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation (“The Regents”) having its statewide administrative offices at 1111 Franklin Street, 12 Floor, Oakland, California 94607-5200. Renovis and The Regents may be referred to herein as a “Party” or, collectively, as “Parties”.
ContractAgreement • January 16th, 2004 • Renovis Inc • Pharmaceutical preparations • California
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT FOR AXON GROWTH TECHNOLOGIESThe Exclusive License Agreement • January 16th, 2004 • Renovis Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT FOR AXON GROWTH TECHNOLOGIES (the “Amendment”) is made and entered into effective as of December 15, 2002 (the “Amendment Effective Date”), by and between RENOVIS, INC., a Delaware corporation (“Renovis”) having its place of business at 270 Littlefield Avenue, South San Francisco, CA 94080, and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation (“The Regents”) whose legal address is 1111 Franklin Street, 12 Floor, Oakland, California 94607-5300, acting through its Office of Technology Licensing at the University of California, Berkeley, California 94720-1620. Renovis and The Regents may be referred to herein as a “Party” or, collectively, as “Parties”.
LICENSE AGREEMENT for [*]/SMALL MOLECULE, AND [*] PROTEIN TECHNOLOGIESLicense Agreement • January 16th, 2004 • Renovis Inc • Pharmaceutical preparations • California
This license agreement (“Agreement”) is made effective this 25th day of November, 2002 (“Effective Date”), between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (“The Regents”), and Renovis, Inc., a Delaware corporation, having a principal place of business at 270 Littlefield Ave., South San Francisco, CA 94080 (“Licensee”).
